Rapid disease progression in epidermal growth factor receptor (EGFR) non–small-cell lung cancer treated with tyrosine kinase inhibitorss has been associated with concomitant mutations. The status of 4 genes (PTEN, TP53, c-MET, IGFR) was evaluated by immunohistochemistry in 51 tumor blocks, and it was correlated with overall response rate, overall survival, and progression-free survival. We point out that immunohistochemistry could be a valid tool to identify PTEN loss. Moreover, our results have shown worse outcomes in terms of progression-free survival, overall survival, and objective response rate in patients with concomitant EGFR mutation and PTEN loss. Furthermore, the coexistence of PTEN loss and IGFR overexpression identifies a potential prognostic ‘signature’ for a subgroup of patients with particularly poor prognosis.
Ferrara, M. G., Martini, M., D'Argento, E., Forcella, C., Vita, E., Di Noia, V. P., Sperduti, I., Bilotta, M., Ribelli, M., Damiano, F. P., Cannella, M. A., Stefani, A., Pilotto, S., Carbone, C., Piro, G., Milella, M., Tortora, G., Bria, E., PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non–small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors, <<CLINICAL LUNG CANCER>>, 2021; (20): 1-10. [doi:10.1016/j.cllc.2020.12.008] [http://hdl.handle.net/10807/178498]
PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non–small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors
Ferrara, Miriam Grazia;Martini, Maurizio;D'Argento, Ettore;Vita, Emanuele;Di Noia, Vincenzo Pio;Ribelli, Marta;Damiano, Francesco Paolo;Cannella, Maria Antonella;Stefani, Alessio;Tortora, Giampaolo;Bria, Emilio
2021
Abstract
Rapid disease progression in epidermal growth factor receptor (EGFR) non–small-cell lung cancer treated with tyrosine kinase inhibitorss has been associated with concomitant mutations. The status of 4 genes (PTEN, TP53, c-MET, IGFR) was evaluated by immunohistochemistry in 51 tumor blocks, and it was correlated with overall response rate, overall survival, and progression-free survival. We point out that immunohistochemistry could be a valid tool to identify PTEN loss. Moreover, our results have shown worse outcomes in terms of progression-free survival, overall survival, and objective response rate in patients with concomitant EGFR mutation and PTEN loss. Furthermore, the coexistence of PTEN loss and IGFR overexpression identifies a potential prognostic ‘signature’ for a subgroup of patients with particularly poor prognosis.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
